To investigate the association between plasma F2-isoprostanes levels and incident clinical fracture risk in older adults with type 2 diabetes (T2D).
Key Findings:
Each SD increase in log plasma F2-isoprostanes was associated with a 93% increase in fracture risk in the T2D group (HR = 1.93, P = .002).
No significant association was found in the nondiabetes group (HR = 0.98, P = .79).
Log plasma F2-isoprostanes correlated with declines in total hip BMD in the T2D group (r = -0.25, P = .003).
Interpretation:
Elevated plasma F2-isoprostanes levels are linked to increased fracture risk in older adults with T2D, suggesting oxidative stress may contribute to bone fragility beyond BMD measurements.
Limitations:
The study is observational, limiting causal inferences.
The cohort may not be representative of all older adults with T2D.
Conclusion:
Plasma F2-isoprostanes may serve as a potential biomarker for assessing fracture risk in individuals with T2D, highlighting the need for further research into oxidative stress and bone health.
